SYDNEY--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has expanded its original agreement with Endoceutics to commercialise Intrarosa® (prasterone) in Australia. Intrarosa is now available in this market as the first and only locally acting DHEA (dehydroepiandrosterone) treatment indicated for postmenopausal women experiencing moderate to severe symptoms associated with vulvovaginal atrophy (VVA).
This is the first product approved to treat sexual symptoms of menopause that contains the active ingredient, prasterone -- also known as dehydroepiandrosterone (DHEA), a dietary supplement that has been previously found to help treat sexual dysfunction associated with menopause.
Market Place
Share
Share
